gdc
FDA Approvals, News & UpdatesMultiple MyelomaNewsworthy

Xpovio a New FDA-Approved Drug for Patients with Multiple Myeloma

August 2019 Vol 5 No 4

In July 2019, the FDA approved Xpovio (selinexor; from Karyopharm Therapeutics), a nuclear export inhibitor, for use in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma after 4 or more therapies, whose disease did not respond to those therapies, including 2 or more proteasome inhibitors, such as Velcade (bortezomib) or Kyprolis (carfilzomib); 2 or more immunomodulatory drugs, such as Revlimid (lenalidomide) or Pomalyst (pomalidomide); and an anti-CD38 monoclonal antibody, such as Darzalex (daratumumab).

“While there is no cure for multiple myeloma, there are FDA-approved treatments to target the cancer and slow down the spread of the disease. Sadly, often over time, patients can exhaust all available treatments and still see their disease progress,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence. “Today we approved a treatment under our accelerated approval program that provides a treatment option for patients with multiple myeloma with no available therapy.”

The FDA approved Xpovio based on a clinical ­trial of patients with multiple myeloma who had previously received at least 4 therapies, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.

Treatment with Xpovio plus dexamethasone showed good overall results, with patients responding to treatment within an average of 4 weeks, and the average length of response was almost 4 months.

Xpovio is associated with a risk for serious side effects to a fetus, blood complications, and thromboembolism.

Recommended For You
Multiple Myeloma
What Your Doctor Should Know: Which Treatment Is Best for a Patient with Relapsed or Refractory Multiple Myeloma?
By Meg Barbor, MPH
Dr. Castillo discussed this topic at the National Comprehensive Cancer Network (NCCN) 2019 Hematologic Malignancies annual meeting, explaining how to approach this challenge in the face of recent advances in multiple myeloma treatment.
Multiple Myeloma
Drugs for Multiple Myeloma
Here are the drugs and financial support services available to patients receiving treatment for Multiple Myeloma.
LeukemiaLymphomaMultiple Myeloma
Working with Your Treatment Team to Decide on the Best Options for You
People who are diagnosed with blood cancer need to learn enough about it without being overwhelmed, and to take part in their treatment decisions. Communicate important personal information to your care team.
Multiple Myeloma
New Study Shows Racial Disparities Still Common in the Treatment of Patients with Multiple Myeloma
By Dana Taylor
Among Americans diagnosed with multiple myeloma, black and Hispanic patients receive their first treatment about 3 months later than white patients. Delays in treatment means unnecessary complications. Closing this racial gap is therefore paramount.
Last modified: August 28, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country